Asian Journal of Surgery最新文献

英文中文

Optimal number of examined lymph nodes for accurate staging and survival in bladder cancer 膀胱癌准确分期和生存率的最佳淋巴结检查数

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.201

Wenke Xu, Yige Jia, Yanxiang Shao, Xiang Li

引用次数: 0

The effectiveness of prehabilitation in patients with pancreatic and periampullary cancers: A systematic review and meta-analysis 胰腺癌和壶腹周围癌患者康复的有效性：一项系统回顾和荟萃分析

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.200

Hoa Ngan Doan, Yoo Jin Choo, Min Cheol Chang

引用次数: 0

A case of vulvar granular cell tumor 外阴颗粒细胞瘤1例

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.206

Yu Zheng, Hong Xu, Rui-heng Zhao, Ru-yue Ma

引用次数: 0

Medial hemiepiphysiodesis with eight-plate for femoral deformity in X-linked hypophosphatemia: A case report 内半截骨骺固定术加8钢板治疗x连锁低磷血症的股骨畸形1例报告

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.205

Yanling Sun , Huan Liu , Mingyong Li , Wuzhou Wu

引用次数: 0

Laparoscopic partial cystectomy for a giant bladder leiomyoma: A case report and literature review 腹腔镜膀胱部分切除术治疗巨大膀胱平滑肌瘤1例报告并文献复习

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.260

Bin Wang, Fachun Tong, Chaochao Hu, Keyuan Zhu

引用次数: 0

Surgical treatment for chronic limb occlusion after endovascular aortic aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) 腹主动脉瘤（AAA）血管内修复（EVAR）术后慢性肢体闭塞的手术治疗

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.240

Haeng Jin Ohe, Sang Dong Kim

引用次数: 0

Laparoscopic PVL and terminal branch portal vein embolization followed by laparoscopic hepatectomy for HCC: With a video vignette 腹腔镜PVL和门静脉末端分支栓塞后肝切除术治疗肝癌：附视频短片

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.280

Qing Yan , Feng-Jie Wang , Jia-Wei He , Jian-Yuan Hu , Eric C.H. Lai , Huan-Wei Chen

Technique

Insufficient future liver remnant (FLR) is one of the most important factors causing the low resection rate of hepatocellular carcinoma(HCC),and surgeons have explored many methods to increase the FLR volume before surgery such as portal vein embolization (PVE), portal vein ligation (PVL) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). However, these methods still have some drawbacks such as long waiting time, insufficient liver hyperplasia, and high postoperative complication and mortality rate. In response to this, we have developed a new surgical method of laparoscopic portal vein ligation and terminal branches portal vein embolization to improve the future liver remnant. This method was performed in a 49-year-old male hepatocellular carcinoma patient. This study introduced this surgical procedure and includes a video vignette for a comprehensive understanding.

Results

This patient underwent the first stage of laparoscopic portal vein ligation and terminal branches portal vein embolization successfully, the operation time was 157 min. No surgery-related complications occurred, and the postoperative hospital stay was 5 days. 28 days after the 1st stage operation, the FLR increased 203.7 cm³(69.4 %). Then, the patients underwent the 2nd step of laparoscopic right hemihepatectomy. The patient recovered well and was discharged 8 days after the surgery.

Conclusion

This two-step hepatectomy strategy is a safe and effective strategy to increase the resectability of HCC patients with insufficient liver volume. It has the advantage of simplifying the surgical procedure and increasing the liver volume obviously.

技术方法肝残馀量不足（FLR）是导致肝细胞癌（HCC）切除率低的重要因素之一，外科医生在术前探索了许多增加FLR容量的方法，如门静脉栓塞（PVE）、门静脉结扎（PVL）和分期肝切除术（ALPPS）相结合的肝分区和门静脉结扎。但这些方法仍存在等待时间长、肝脏增生不充分、术后并发症和死亡率高等缺点。针对此，我们开发了腹腔镜门静脉结扎及门静脉末支栓塞的新手术方法，以改善未来肝残。此方法用于一位49岁男性肝癌患者。本研究介绍了该手术程序，并包括一个视频短片，以全面了解。结果该患者成功行第一期腹腔镜门静脉结扎术及门静脉末支栓塞术，手术时间157 min。无手术相关并发症发生，术后住院5天。一期手术后28天，FLR增加203.7 cm3（69.4%）。然后行第二步腹腔镜右半肝切除术。患者恢复良好，术后8天出院。结论两步肝切除术是提高肝容量不足的HCC患者可切除性的一种安全有效的策略。它具有简化手术程序和明显增加肝脏体积的优点。

{"title":"Laparoscopic PVL and terminal branch portal vein embolization followed by laparoscopic hepatectomy for HCC: With a video vignette","authors":"Qing Yan , Feng-Jie Wang , Jia-Wei He , Jian-Yuan Hu , Eric C.H. Lai , Huan-Wei Chen","doi":"10.1016/j.asjsur.2025.07.280","DOIUrl":"10.1016/j.asjsur.2025.07.280","url":null,"abstract":"<div><h3>Technique</h3><div>Insufficient future liver remnant (FLR) is one of the most important factors causing the low resection rate of hepatocellular carcinoma(HCC),and surgeons have explored many methods to increase the FLR volume before surgery such as portal vein embolization (PVE), portal vein ligation (PVL) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). However, these methods still have some drawbacks such as long waiting time, insufficient liver hyperplasia, and high postoperative complication and mortality rate. In response to this, we have developed a new surgical method of laparoscopic portal vein ligation and terminal branches portal vein embolization to improve the future liver remnant. This method was performed in a 49-year-old male hepatocellular carcinoma patient. This study introduced this surgical procedure and includes a video vignette for a comprehensive understanding.</div></div><div><h3>Results</h3><div>This patient underwent the first stage of laparoscopic portal vein ligation and terminal branches portal vein embolization successfully, the operation time was 157 min. No surgery-related complications occurred, and the postoperative hospital stay was 5 days. 28 days after the 1st stage operation, the FLR increased 203.7 cm<sup>3</sup>(69.4 %). Then, the patients underwent the 2nd step of laparoscopic right hemihepatectomy. The patient recovered well and was discharged 8 days after the surgery.</div></div><div><h3>Conclusion</h3><div>This two-step hepatectomy strategy is a safe and effective strategy to increase the resectability of HCC patients with insufficient liver volume. It has the advantage of simplifying the surgical procedure and increasing the liver volume obviously.</div></div>","PeriodicalId":55454,"journal":{"name":"Asian Journal of Surgery","volume":"49 2","pages":"Pages 715-717"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and risk factors of sarcopenia in patients after kidney transplantation: An updated systematic review and meta-analysis 肾移植后肌减少症的患病率和危险因素：最新的系统回顾和荟萃分析

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.09.040

Yu-Chi Su , Yu-Ching Lin , Yu-Tzu Chang , Chia-Ter Chao , Jen-Hao Yeh , Tsai-Chieh Ling , Deng-Chi Yang , Shen-Shin Chang , Chien-Yao Sun

Background/objective

This study aimed to investigate the prevalence and risk factors of sarcopenia in patients who have undergone kidney transplantation (KT).

Methods

A comprehensive search of PubMed, Cochrane Library, and Embase databases was conducted until Oct. 23, 2023. Sarcopenia was defined as the presence of low muscle mass, strength, and/or low physical performance. The outcomes of interest were the prevalence and risk factors associated with sarcopenia.

Results

A total of 12 studies involving 1289 participants were included in quantitative analysis. The pooled result revealed an overall prevalence of sarcopenia in KT recipients of 15.8 % (95 % CI: 11.2 %–21.9 %, I² = 83.9 %). Subgroup analysis suggested that the variation in criteria for diagnosing sarcopenia (p < 0.001) and geographical regions (p < 0.001) accounted for the heterogeneity. Meta-regression analysis demonstrated that studies including patients with better preserved graft function, as assessed by estimated glomerular filtration rate, were associated with a lower prevalence of sarcopenia (β = −0.055, p = 0.032). The meta-analysis showed that KT patients with sarcopenia had a significantly lower body mass index (BMI) compared to those without (weighted mean difference: −4.457 kg/m², 95 % CI: −6.484 to −2.429).

Conclusion

This meta-analysis found a 15.8 % prevalence of sarcopenia among KT recipients, with significant variations due to diagnostic criteria and geographical regions. Recipients with better graft function and higher body mass index were less likely to have sarcopenia. Longitudinal studies are needed to clarify the impact of sarcopenia in KT recipients.

背景/目的本研究旨在调查肾移植（KT）患者肌肉减少症的患病率及危险因素。方法综合检索PubMed、Cochrane Library和Embase数据库，检索时间截止到2023年10月23日。肌肉减少症被定义为肌肉量、力量和/或体能低下。研究的结果是与肌肉减少症相关的患病率和危险因素。结果共纳入12项研究，1289名受试者。综合结果显示，KT受体中肌肉减少症的总体患病率为15.8% （95% CI: 11.2% - 21.9%, I2 = 83.9%）。亚组分析表明，诊断肌肉减少症的标准差异（p < 0.001）和地理区域差异（p < 0.001）解释了异质性。meta -回归分析表明，研究中包含了保存较好移植物功能的患者，通过估计肾小球滤过率来评估，与较低的肌少症患病率相关（β = - 0.055, p = 0.032）。荟萃分析显示，骨骼肌减少症的KT患者的体重指数（BMI）明显低于没有骨骼肌减少症的患者（加权平均差：- 4.457 kg/m2, 95% CI: - 6.484至- 2.429）。该荟萃分析发现，在KT受体中，肌肉减少症的患病率为15.8%，由于诊断标准和地理区域的差异，存在显著差异。移植物功能较好、体重指数较高的受者发生肌肉减少症的可能性较低。需要进行纵向研究来阐明肌减少症对KT受体的影响。

{"title":"Prevalence and risk factors of sarcopenia in patients after kidney transplantation: An updated systematic review and meta-analysis","authors":"Yu-Chi Su , Yu-Ching Lin , Yu-Tzu Chang , Chia-Ter Chao , Jen-Hao Yeh , Tsai-Chieh Ling , Deng-Chi Yang , Shen-Shin Chang , Chien-Yao Sun","doi":"10.1016/j.asjsur.2025.09.040","DOIUrl":"10.1016/j.asjsur.2025.09.040","url":null,"abstract":"<div><h3>Background/objective</h3><div>This study aimed to investigate the prevalence and risk factors of sarcopenia in patients who have undergone kidney transplantation (KT).</div></div><div><h3>Methods</h3><div>A comprehensive search of PubMed, Cochrane Library, and Embase databases was conducted until Oct. 23, 2023. Sarcopenia was defined as the presence of low muscle mass, strength, and/or low physical performance. The outcomes of interest were the prevalence and risk factors associated with sarcopenia.</div></div><div><h3>Results</h3><div>A total of 12 studies involving 1289 participants were included in quantitative analysis. The pooled result revealed an overall prevalence of sarcopenia in KT recipients of 15.8 % (95 % CI: 11.2 %–21.9 %, I<sup>2</sup> = 83.9 %). Subgroup analysis suggested that the variation in criteria for diagnosing sarcopenia (p < 0.001) and geographical regions (p < 0.001) accounted for the heterogeneity. Meta-regression analysis demonstrated that studies including patients with better preserved graft function, as assessed by estimated glomerular filtration rate, were associated with a lower prevalence of sarcopenia (β = −0.055, p = 0.032). The meta-analysis showed that KT patients with sarcopenia had a significantly lower body mass index (BMI) compared to those without (weighted mean difference: −4.457 kg/m<sup>2</sup>, 95 % CI: −6.484 to −2.429).</div></div><div><h3>Conclusion</h3><div>This meta-analysis found a 15.8 % prevalence of sarcopenia among KT recipients, with significant variations due to diagnostic criteria and geographical regions. Recipients with better graft function and higher body mass index were less likely to have sarcopenia. Longitudinal studies are needed to clarify the impact of sarcopenia in KT recipients.</div></div>","PeriodicalId":55454,"journal":{"name":"Asian Journal of Surgery","volume":"49 2","pages":"Pages 633-641"},"PeriodicalIF":3.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146102922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated transcriptomic analysis identifies BCAT1 as a prognostic and immune-related biomarker in gastric cancer 综合转录组学分析确定BCAT1是胃癌预后和免疫相关的生物标志物

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.10.100

Yuxi Li , Shiyan Zhang , Yaoyu Zhang , Lin Zhang

引用次数: 0

Median nerve entrapment should not be ignored in the medial epicondyle fracture of the humerus 肱骨内上髁骨折不能忽视正中神经卡压

IF 3.8 3区医学 Q1 SURGERY

Asian Journal of Surgery

Pub Date : 2026-02-01 DOI: 10.1016/j.asjsur.2025.07.255

Fei Qiao, Rui Wang

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Asian Journal of Surgery

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀